Indication: Rare Tumors
ADVL1622, Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors.
Sub-indication: Rare Tumors
Principal Investigator: Kerry K. McGowan, M.D.Norton Children's Cancer Institute, affiliated with the UofL School of Medicine
Sponsor: Children's Oncology Group (COG)